The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors
Abstract
Activating neurotrophic receptor kinase ( NTRK ) fusions define certain pediatric mesenchymal tumors, including infantile fibrosarcoma and cellular mesoblastic nephroma. Traditionally, molecular confirmation of these fusions has included either fluorescent in situ hybridization for ETV6 rearrangements or reverse-transcriptase polymerase chain reaction for the classic ETV6-NTRK3 fusion. However, these methods overlook variant NTRK rearrangements, which are increasingly appreciated as recurrent events in a subset of pediatric mesenchymal tumors. New therapeutic agents successfully target these fusions and may prevent morbid surgeries in very young children, making recognition of tumors harboring NTRK rearrangements of increasing importance. We evaluated the performance of immunohistochemical (IHC) staining using pan-Trk and TrkA antibodies in 79 pediatric mesenchymal tumors. Negative controls included pediatric mesenchymal tumors not harboring (n=28) or not expected to harbor (n=22) NTRK fusions. NTRK rearrangements were detected predominantly by DNA-based next-generation sequencing assays, specifically UW OncoPlex and UCSF500 Cancer Gene Panel. Pan-Trk IHC (EPR17341) was 97% sensitive and 98% specific for the presence of an NTRK rearrangement, and TrkA IHC (EP1058Y) was 100% sensitive and 63% specific for the presence of an NTRK rearrangement. Tumors with NTRK1 or NTRK2 rearrangements showed cytoplasmic staining, whereas tumors with NTRK3 rearrangements showed nuclear +/− cytoplasmic staining. We conclude that pan-Trk IHC is a highly sensitive and specific marker for NTRK rearrangements in pediatric mesenchymal tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Self-citation
Cited by
NTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,485
NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
Solomon, J. P., Linkov, I., Rosado, A., Mullaney, K., Rosen, E. Y., Frosina, D., Jungbluth, A. A., Zehir, A., Benayed, R., Drilon, A., et al. (2020) · Modern Pathology · doi:10.1038/s41379-019-0324-7 · Cited by 546
Molecular characterization of cancers with NTRK gene fusions
Gatalica, Z., Xiu, J., Swensen, J., & Vranic, S. (2019) · Modern Pathology · doi:10.1038/s41379-018-0118-3 · Cited by 486
Marchiò, C., Scaltriti, M., Ladanyi, M., Iafrate, A. J., Bibeau, F., Dietel, M., Hechtman, J. F., Troiani, T., López-Rios, F., Douillard, J.-Y., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz204 · Cited by 372
Identifying patients with NTRK fusion cancer
Solomon, J. P., Benayed, R., Hechtman, J. F., & Ladanyi, M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz384 · Cited by 270
Metadata
- Authors
- Rudzinski, E. R., Lockwood, C. M., Stohr, B. A., Vargas, S. O., Sheridan, R., Black, J. O., Rajaram, V., Laetsch, T. W., & Davis, J. L.
- Venue
- American Journal of Surgical Pathology
- Published
- 2018-07
- Volume
- 42
- Issue
- 7
- Pages
- 927-935
- ISSN
- 0147-5185 (ISSN-L)
- OpenAlex
- W2800972091
- Cited by
- 213
- References
- 1
- FWCI
- 20.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors. https://app.cochat.ai/papers/10.1097/pas.0000000000001062
- The paper
- Rudzinski, E. R., Lockwood, C. M., Stohr, B. A., Vargas, S. O., Sheridan, R., Black, J. O., Rajaram, V., Laetsch, T. W., & Davis, J. L. (2018). Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors. American Journal of Surgical Pathology. https://doi.org/10.1097/pas.0000000000001062
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.